If You Invested $1,000 in Atyr Pharma Inc (ATYR)
This article analyzes the historical performance of Atyr Pharma Inc (ATYR) stock, demonstrating the significant losses an investment of $1,000 would have incurred over 1, 5, and 10 years compared to the S&P 500. It also provides a detailed overview of Atyr Pharma, including its focus on tRNA synthetase biology, its lead therapeutic candidate efzofitimod for interstitial lung disease, and its broader clinical programs and discovery platform. Financial metrics and comparisons to similar stocks are included, alongside a summary of the company's public status and risks.
Class Action Filed Against aTyr Pharma, Inc. (ATYR) Over Securities Violations - Contact Levi & Korsinsky Today
Levi & Korsinsky, LLP has filed a class action securities lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR) alleging securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims aTyr made misleading statements about the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage. This alleged deception led to an 83.2% stock price decline on September 15, 2025, after the company announced its EFZO-FIT study did not meet its primary endpoint.
JonesTrading Maintains ATyr Pharma(ATYR.US) With Hold Rating
JonesTrading has reiterated its Hold rating for ATyr Pharma (ATYR.US). This indicates a neutral outlook on the company's stock performance from the analyst firm.
Price to book forward of aTyr Pharma, Inc. – NASDAQ:ATYR
This article provides access to the "Price to book forward" financial metric for aTyr Pharma, Inc. (NASDAQ: ATYR) on TradingView. It highlights that the market was closed at the time of access and offers no specific financial data within the provided text, instead serving as a portal to financial information.
Burned by aTyr Pharma, Inc.? Contact Levi & Korsinsky to SueWallSt And Fight Back
Levi & Korsinsky has filed a class action lawsuit against aTyr Pharma, Inc. on behalf of investors who experienced losses due to alleged securities fraud between November 7, 2024, and September 12, 2025. The firm, known for securing significant amounts for aggrieved shareholders, encourages affected investors to contact them for legal action. They also promote their SueWallSt podcast and WhatsApp channel for updates on class action news.
Investors SueWallSt Over aTyr Pharma, Inc. Stock Drop - Contact Levi & Korsinsky to Join
A class action lawsuit has been filed against aTyr Pharma, Inc. on behalf of investors who incurred losses due to alleged securities fraud between November 7, 2024, and September 12, 2025. Investors are encouraged to contact Levi & Korsinsky through SueWallSt if they suffered losses, to potentially join the lawsuit. Levi & Korsinsky, a firm with a strong track record in securities litigation, is representing the investors.
Join Class Action to Recover Losses from aTyr Pharma, Inc. (ATYR)
Levi & Korsinsky LLP has filed a class action lawsuit against aTyr Pharma, Inc. (ATYR) on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims that the company made misleading statements about the efficacy of its drug Efzofitimod, particularly its ability to taper steroid usage. This led to an 83.2% stock price decline on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint.
Investors in aTyr Pharma, Inc. (ATYR): Protect Your Rights - Contact Levi & Korsinsky Before December 8, 2025
Levi & Korsinsky LLP is inviting investors in aTyr Pharma, Inc. (NASDAQ: ATYR) to contact them regarding a class action securities lawsuit. The lawsuit seeks to recover losses for shareholders affected by alleged securities fraud between November 7, 2024, and September 12, 2025, concerning misleading statements about the efficacy of their drug Efzofitimod. The stock price dropped significantly after the company announced its EFZO-FIT study did not meet its primary endpoint.
aTyr Pharma (ATYR) Stock Forecast & Analyst Ratings
This article provides a stock forecast and analyst ratings for aTyr Pharma (ATYR). It includes information on how analysts rate the stock, future price targets, and an overview of the company's financial health and business model. Investors can use this data to make informed decisions about ATYR.
aTyr Pharma, Inc. Actuals & Estimates (NASDAQ:ATYR)
This article provides an overview of aTyr Pharma, Inc. (NASDAQ: ATYR) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers frequently asked questions about the company's stock, market capitalization, earnings reports, and volatility.
ATYR Forecast — Price Target — Prediction for 2027
The article provides a forecast for aTyr Pharma, Inc. (ATYR) stock, including a 1-year price target of $2.86 based on analyst estimates. It details the company's current stock price, historical highs and lows, market capitalization, and upcoming earnings report. The piece also summarizes analyst opinions on future price movements and offers financial performance metrics, reinforcing that the information is not investment advice.
ATYR Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and events related to aTyr Pharma (ATYR), including its Q1 earnings beat, advancements in efzofitimod development for pulmonary sarcoidosis, and a past shareholder lawsuit investigation. It also details broader market movements on May 15, 2026, where major averages closed lower due to tech stock underperformance, rising U.S. Treasury yields, and an increase in oil prices. The market summary includes stock news, Wall Street calls, industry news, top movers, and earnings reports, with aTyr Pharma specifically mentioned for a productive start to 2026.
aTyr Pharma Ord Shs (LIFE) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for aTyr Pharma Ord Shs (LIFE), detailing its current earnings forecast score, analyst ratings, and future EPS and revenue growth estimates. Based on 9 analysts, the stock has a "Buy" trend with an 81.20% upside in its target price. The company's expected revenue for the next quarter is $117.14M, and its EPS is projected at $0.24.
aTyr Pharma Inc (ATYR) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of aTyr Pharma Inc's (ATYR) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also displays current stock data for ATYR, including its market capitalization.
FMR LLC Significantly Reduces Holdings in aTyr Pharma Inc
FMR LLC has significantly reduced its stake in aTyr Pharma Inc, selling 8,770,943 shares at $0.5465 each, decreasing its position by 59.64%. Despite this, the transaction maintained FMR LLC's overall portfolio position of 6.10% in aTyr Pharma. This move suggests potential concerns about aTyr Pharma's financial stability, as the biotech company faces significant stock price decline and a low GF Score of 19/100, indicating poor future performance potential.
aTyr Pharma Granted Nasdaq Extension to Regain Compliance
aTyr Pharma has received an extension from Nasdaq until November 30, 2026, to regain compliance with the minimum $1.00 bid price requirement. The company was initially notified on December 4, 2025, and granted an extension on June 3, 2026, to avoid delisting. Analyst sentiment on ATYR stock is a "Buy" with a $3.50 price target, though TipRanks’ AI Analyst Spark rates it as "Neutral" due to weak financial performance and bearish technicals.
aTyr Pharma Company Profile & Introduction
aTyr Pharma is a biotherapeutics company focused on developing novel immune-modulating therapeutics. The company's pipeline includes therapies for interstitial lung disease and other rare immune-mediated diseases. aTyr Pharma utilizes its tRNA synthetase biology platform to discover and develop its innovative treatments.
aTyr Pharma Granted Nasdaq Extension to Regain Compliance
aTyr Pharma has received an extension from Nasdaq until November 30, 2026, to regain compliance with the minimum $1.00 bid price requirement. The company initially received a deficiency notice on December 4, 2025, and failure to meet the new deadline could lead to delisting. Analysts currently rate ATYR as a Buy with a $3.50 target, though TipRanks' AI analyst, Spark, views it as Neutral due to weak financial performance and bearish technicals.
Insider Buyers At aTyr Pharma Likely Disappointed With 19% Slide
Insiders at aTyr Pharma, including Paul Schimmel, bought US$911.8k worth of stock at an average price of US$0.91 over the past year. Despite their confidence, the stock has since slid by 19%, reducing their investment to US$442.1k. While insider ownership stands at 2.5%, the recent dip highlights a potential disappointment for these buyers.
Insider Buyers At aTyr Pharma Likely Disappointed With 19% Slide
Insiders at aTyr Pharma are likely disappointed after the stock slid 19%, significantly reducing the value of their recent purchases. Despite a large purchase by one insider at a higher price, suggesting confidence, the current market performance has resulted in considerable losses on their initial US$911.8k investment. While individual insider ownership is modest at 2.5%, the article concludes that there's nothing to suggest insiders are doubting the company's future, but advises investors to also consider the inherent risks.
aTyr Pharma Received Notice of Noncompliance
aTyr Pharma (ATYR) announced on June 3, 2026, that it received a Nasdaq letter granting an additional 180 days, until November 30, 2026, to comply with the $1.00 minimum bid price requirement. The notice does not immediately affect its Nasdaq listing, and the company may consider a reverse stock split if necessary, as failure to comply could lead to delisting. This information is based on an SEC filing from June 8, 2026.
aTyr Pharma (NASDAQ: ATYR) wins second Nasdaq deadline to fix sub-$1 share price
aTyr Pharma (NASDAQ: ATYR) has received a second 180-day extension from Nasdaq to regain compliance with the exchange's minimum $1.00 bid price requirement. The company now has until November 30, 2026, to ensure its stock trades at or above $1.00 for at least 10 consecutive business days, potentially through a reverse stock split. This extension is granted because aTyr meets other Nasdaq listing standards, and its shares will continue to trade on the Nasdaq Capital Market while it addresses the deficiency.
FMR LLC discloses 5.94M-share stake in ATYR (NASDAQ: ATYR) Amendment No.14
FMR LLC has filed an Amendment No. 14 to a Schedule 13G/A, disclosing beneficial ownership of 5,935,900 shares of ATYR PHARMA INC (NASDAQ: ATYR) common stock, which represents 6.1% of the class. The filing specifies FMR LLC's sole voting and dispositive powers, along with Abigail P. Johnson's dispositive power. The document also references a 13d-1(k) agreement and powers of attorney.
aTyr Pharma (ATYR) Price Target Decreased by 37.13% to 6.48
This article reports that the price target for aTyr Pharma (ATYR) has been decreased by 37.13%, bringing it down to $6.48. No further details about the reasons for this change or the analyst responsible are provided in this brief update.
aTyr Pharma (ATYR) Price Target Decreased by 37.13% to 6.48
This article reports a significant decrease in the price target for aTyr Pharma (ATYR) shares. The new target is $6.48, representing a 37.13% reduction. Further details about the reasons for this change or the analyst responsible are not provided.
aTyr Pharma (ATYR) refocuses efzofitimod after EFZO-FIT miss with new Phase 3 sarcoidosis trial
aTyr Pharma is repositioning its lead drug, efzofitimod, for pulmonary sarcoidosis after its Phase 3 EFZO-FIT trial missed its primary endpoint (steroid dose reduction). Despite this, the drug showed positive results in steroid-free rates and quality of life. The company has received FDA feedback supporting a new Phase 3 trial (C-006) focusing on restrictive pulmonary sarcoidosis with forced vital capacity (FVC) as the primary endpoint.
aTYR Pharma director Paul Schimmel buys $49,630 in common stock
aTYR Pharma Inc. director Paul Schimmel recently purchased 100,000 shares of the company's common stock for $49,630, with the stock trading near its 52-week low. This insider buy increases his indirect holdings to over 779,000 shares through a trust and over 1.4 million shares directly. The purchase comes as investment analysis suggests ATYR is undervalued, with a fair value of $0.61, and the company prepares for a new Phase 3 study for its drug efzofitimod.
Director at aTyr Pharma (NASDAQ: ATYR) adds 100K shares
A director at aTyr Pharma (NASDAQ: ATYR), Paul Schimmel, reported an open-market purchase of 100,000 shares of the company's common stock. The transaction occurred on May 27, 2026, at a weighted average price of $0.4963 per share, with individual trades ranging from $0.4907 to $0.50. These shares are held indirectly through entities associated with Schimmel, such as the Schimmel Revocable Trust and Paul Schimmel Prototype PSP.
aTyr Pharma plans new phase 3 trial for pulmonary sarcoidosis drug
aTyr Pharma announced plans to submit an investigational new drug application in June 2026 for a new Phase 3 study of efzofitimod for pulmonary sarcoidosis. The company received feedback from the FDA, leading to a new trial design using forced vital capacity (FVC) as the primary endpoint and King’s Sarcoidosis Questionnaire-Lung (KSQ-Lung) as the key secondary endpoint. The proposed global study will enroll approximately 372 patients and assess efzofitimod's efficacy and safety.
ATyr Pharma Raised to Buy From Hold by Freedom Broker
Freedom Broker has upgraded its rating for ATyr Pharma from Hold to Buy. This change in rating suggests a more positive outlook on the company's stock from the brokerage firm.
aTyr Pharma stock (US53227K1025): clinical pipeline update keeps biotech in focus
aTyr Pharma, a clinical-stage biotech focused on immune-modulating protein therapeutics, remains a key focus for investors due to recent pipeline and financing updates. The company is advancing its lead candidate for interstitial lung diseases through mid-stage trials, with its business model highly dependent on clinical trial outcomes and capital market conditions. For US investors, the stock offers exposure to high-risk, early-stage biopharmaceutical innovation on the Nasdaq, with significant upside potential but also considerable scientific, regulatory, and financial uncertainties.
Freedom Capital Markets Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $3.5
Freedom Capital Markets has initiated coverage of ATyr Pharma (ATYR.US) with a 'Buy' rating. The firm has set a target price of $3.5 for the biopharmaceutical company's stock. This initiation suggests a positive outlook on ATyr Pharma's future performance by Freedom Capital Markets.
ATYR Upgraded by Freedom Broker -- Price Target Raised to $3.50
ATyr Pharma Inc. (ATYR) has been upgraded from a 'Hold' to a 'Buy' rating by Freedom Broker analyst Ilya Zubkov, with its price target significantly raised from $1.00 to $3.50. Despite this positive analyst outlook, GuruFocus indicates that ATYR is currently 14.4% overvalued with a GF Value™ of $0.47 against its trading price of $0.54, and has a low GF Score™ of 24/100, reflecting challenges in financial performance and profitability. Investors are advised to consider the mixed signals, including the optimism from analysts against the company's valuation and financial strength metrics.
aTyr Pharma upgraded to Buy from Hold at Freedom Broker
Freedom Broker upgraded aTyr Pharma (ATYR) to a Buy rating from Hold, increasing its price target to $3.50 from $1. This upgrade follows the FDA's confirmation for continuing efzofitimod development in chronic symptomatic pulmonary sarcoidosis, removing some uncertainty. The firm highlighted the drug's ultra-orphan profile and potential in orphan diseases as key reasons for the improved rating.
Atyr plans new global clinical trial of efzofitimod in pulmonary sarcoidosis
Atyr Pharma plans to launch a new global Phase 3 clinical trial (C-006) for its investigational therapy, efzofitimod, to treat pulmonary sarcoidosis patients with a restrictive lung profile. This decision follows discussions with the FDA, which will emphasize forced vital capacity (FVC) as the primary outcome. The previous EFZO-FIT trial failed its main goal but showed benefits in quality of life and corticosteroid reduction.
Number of shareholders of aTyr Pharma, Inc. – LS:A2PM86
The article provides a brief mention of the number of shareholders for aTyr Pharma, Inc. (LS:A2PM86). The content is primarily structural navigation and copyright information for TradingView and related financial data services, with little substantive detail about the shareholder count itself. It appears to be a stub or a placeholder for financial data that is not explicitly presented in the provided text.
Number of shareholders of aTyr Pharma, Inc. – NASDAQ:ATYR
This article provides details on the number of shareholders for aTyr Pharma, Inc. (NASDAQ: ATYR) as listed on TradingView. It appears to be a financial data page rather than an analytical piece, offering numerical values for periods with changes and percentage changes.
Atyr Pharma: Q1 Earnings Snapshot
Atyr Pharma Inc. (ATYR) reported a first-quarter loss of $10.8 million, or 11 cents per share. The company's shares closed at 56 cents, a significant drop from $3.03 a year ago. This financial data was generated by Automated Insights using Zacks Investment Research.
[10-Q] aTYR PHARMA INC Quarterly Earnings Report
aTyr Pharma, Inc. has filed its Quarterly Earnings Report (Form 10-Q) for the period ended March 31, 2026. The clinical-stage biotechnology company reported a consolidated net loss of $10.8 million for the three months ended March 31, 2026, and highlighted its ongoing efforts in developing efzofitimod for interstitial lung disease, including plans for a new Phase 3 study in pulmonary sarcoidosis. The report also notes the termination of its collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd., effective August 10, 2026, which will return global rights for efzofitimod to aTyr Pharma.
aTyr Pharma Inc options imply 30.5% move in share price post-earnings
Options trading for aTyr Pharma Inc. (ATYR) suggests a potential 30.5% shift in its share price following its upcoming earnings release. While current options activity indicates a significant move, the median price movement for the company over the last eight quarters has been 5.9%. Calls are notably outnumbering puts by 142:1 in pre-earnings options volume.
Atyr Pharma: Q1 Earnings Snapshot
Atyr Pharma Inc. (ATYR) reported a first-quarter loss of $10.8 million, translating to 11 cents per share. The company's shares closed at 56 cents, a significant decrease from $3.03 a year ago. This financial summary was compiled using data from Zacks Investment Research.
aTyr Pharma (NASDAQ: ATYR) details Q1 2026 loss and Phase 3 plan
aTyr Pharma reported a net loss of $10.8 million for Q1 2026, an improvement from $14.9 million in Q1 2025. The company plans to submit an Investigational New Drug (IND) application in June 2026 for a global Phase 3 study of efzofitimod in pulmonary sarcoidosis and is on track to complete enrollment for its Phase 2 EFZO-CONNECT SSc-ILD trial in the first half of 2026. aTyr ended the quarter with $68.3 million in cash, cash equivalents, restricted cash, and investments.
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
aTyr Pharma (NASDAQ: ATYR) announced its first quarter 2026 results and provided a corporate update, including a clear path forward for efzofitimod in pulmonary sarcoidosis following a Type C meeting with the FDA. The company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis, using FVC as the primary endpoint. Additionally, aTyr is on track to complete enrollment in the Phase 2 EFZO-CONNECT™ study for SSc-ILD in the first half of 2026 and ended the quarter with $68.3 million in cash and investments.
Biotech plans global lung disease trial after FDA talks, holds $68M cash
aTyr Pharma reported Q1 2026 results, ending March 31, 2026, with $68.3 million in cash. The company plans to file an IND in June 2026 for a new global Phase 3 trial of efzofitimod in pulmonary sarcoidosis, following positive FDA Type C meeting feedback. Additionally, aTyr is on track to complete enrollment for its Phase 2 EFZO-CONNECT SSc-ILD study in the first half of 2026 and released promising preclinical data for ATYR0101.
Atyr Pharma: Q1 Earnings Snapshot
Atyr Pharma Inc. (ATYR) reported a loss of $10.8 million in its first quarter, amounting to 11 cents per share. The company's stock closed at 56 cents, a significant drop from $3.03 a year ago. This financial summary was generated using data from Zacks Investment Research.
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
aTyr Pharma announced its first quarter 2026 results and provided a corporate update, highlighting plans to continue developing efzofitimod for pulmonary sarcoidosis. The company will submit an IND in June 2026 for a Phase 3 study in chronic, symptomatic pulmonary sarcoidosis patients with restrictive lung disease, using FVC as the primary endpoint. They also reported $68.3 million in cash and investments at the end of Q1 2026.
12 Health Care Stocks Moving In Thursday's Intraday Session
This article lists several healthcare stocks that experienced significant intraday movement on Thursday. It details both gainers like Quantum Cyber and Innate Pharma, with some rising over 70%, and losers such as MDxHealth and Regenxbio, which saw declines of over 37%, often correlating with recent earnings reports.
aTyr Pharma to Participate in Upcoming Investor Conferences
aTyr Pharma, Inc. (Nasdaq: ATYR) announced its participation in two upcoming investor conferences: the RBC Capital Markets Global Healthcare Conference on May 20, 2026, and the Jefferies Global Healthcare Conference on June 4, 2026. President and CEO Sanjay S. Shukla will speak at the Jefferies event, which will also feature one-on-one meetings with investors and a webcast. The company, a clinical-stage biotechnology firm, focuses on developing medicines from its proprietary tRNA synthetase platform.
Biotech developing lung disease drug plans Jefferies fireside chat
aTyr Pharma (Nasdaq: ATYR) announced its participation in two upcoming investor conferences: the RBC Capital Markets Global Healthcare Conference on May 20, 2026, and the Jefferies Global Healthcare Conference on June 4, 2026. At Jefferies, President and CEO Sanjay S. Shukla will conduct a fireside chat, which will be webcast. The company is clinical-stage, specializing in therapies for fibrosis and inflammation, with their lead candidate, efzofitimod, targeting interstitial lung disease.
Director Jane Gross (ATYR) awarded 50,000 aTyr Pharma stock options at $0.95
aTyr Pharma director Jane A. Gross was granted 50,000 stock options at an exercise price of $0.95 per share as part of her non-employee director compensation. These options will vest in full on the earlier of May 11, 2027, or the company’s 2027 Annual Meeting of Stockholders, provided she continues her service on the Board. This transaction, detailed in a Form 4 SEC filing, increases her direct holdings to 50,000 stock options.
